1. Home
  2. GUT vs ERAS Comparison

GUT vs ERAS Comparison

Compare GUT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GUT
  • ERAS
  • Stock Information
  • Founded
  • GUT 1999
  • ERAS 2018
  • Country
  • GUT United States
  • ERAS United States
  • Employees
  • GUT N/A
  • ERAS N/A
  • Industry
  • GUT Trusts Except Educational Religious and Charitable
  • ERAS Biotechnology: Pharmaceutical Preparations
  • Sector
  • GUT Finance
  • ERAS Health Care
  • Exchange
  • GUT Nasdaq
  • ERAS Nasdaq
  • Market Cap
  • GUT 415.5M
  • ERAS 448.1M
  • IPO Year
  • GUT N/A
  • ERAS 2021
  • Fundamental
  • Price
  • GUT $5.36
  • ERAS $1.41
  • Analyst Decision
  • GUT
  • ERAS Strong Buy
  • Analyst Count
  • GUT 0
  • ERAS 5
  • Target Price
  • GUT N/A
  • ERAS $5.70
  • AVG Volume (30 Days)
  • GUT 176.3K
  • ERAS 1.2M
  • Earning Date
  • GUT 01-01-0001
  • ERAS 03-26-2025
  • Dividend Yield
  • GUT 10.93%
  • ERAS N/A
  • EPS Growth
  • GUT N/A
  • ERAS N/A
  • EPS
  • GUT N/A
  • ERAS N/A
  • Revenue
  • GUT N/A
  • ERAS N/A
  • Revenue This Year
  • GUT N/A
  • ERAS N/A
  • Revenue Next Year
  • GUT N/A
  • ERAS N/A
  • P/E Ratio
  • GUT N/A
  • ERAS N/A
  • Revenue Growth
  • GUT N/A
  • ERAS N/A
  • 52 Week Low
  • GUT $4.60
  • ERAS $1.41
  • 52 Week High
  • GUT $7.38
  • ERAS $3.45
  • Technical
  • Relative Strength Index (RSI)
  • GUT 45.76
  • ERAS 25.44
  • Support Level
  • GUT $5.32
  • ERAS $1.52
  • Resistance Level
  • GUT $5.50
  • ERAS $1.76
  • Average True Range (ATR)
  • GUT 0.06
  • ERAS 0.13
  • MACD
  • GUT -0.01
  • ERAS 0.00
  • Stochastic Oscillator
  • GUT 22.22
  • ERAS 0.00

About GUT Gabelli Utility Trust (The)

Gabelli Utility Trust operates as a diversified closed-end investment management company. The fund's primary objective is the long-term growth of capital and income. To achieve its objective, the fund may invest its assets in common stocks and other securities of foreign and domestic companies involved in providing products, services, or equipment for the generation or distribution of electricity, gas, & water; and telecommunications services or infrastructure operations. It invests in various sectors, of which Electric Integrated, Water, Telecommunications, and U.S. Government Obligations and others.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: